Prescription Rationality Assessment - Nephrotic Syndrome (16-year-old)

Drug-by-Drug Rationality Analysis

1. Inj. Pantoprazole 40mg OD - RATIONAL

• Efficacy: Proton pump inhibitors (PPIs) are standard gastric cytoprotection when using high-dose systemic steroids. KDIGO 2025 and standard pediatric nephrotic syndrome guidelines endorse gastroprotection as part of admission protocol alongside steroids. The Ashford St. Peter's 2024 guideline explicitly lists "gastroprotection" as a mandatory co-prescription with prednisolone/methylprednisolone.
• Safety: Safe in adolescents. IV formulation is appropriate in a hospitalized, acutely unwell patient.
• Cost: Moderate cost; generic pantoprazole is widely available and affordable in India. Rational choice vs. higher-cost branded PPIs.
• Verdict: ✅ Rational - appropriate dose, route, and indication.

2. Inj. Emeset (Ondansetron) 4mg TDS - CONDITIONALLY RATIONAL

• Efficacy: Ondansetron is a 5-HT3 antagonist with well-established anti-emetic efficacy. Standard dose in adolescents is 4-8mg.
• Safety: Safe in this age group. TDS dosing (3 times a day) is more aggressive than typically required unless there is active vomiting. Should be stepped down once symptoms settle.
• Cost: Generic ondansetron injection is low-cost in India.
• Concern: TDS frequency is high for prophylactic use; should be PRN (as-needed) unless vomiting is persistent. Overuse carries small risk of QTc prolongation.
• Verdict: ⚠️ Conditionally rational - appropriate drug, but TDS frequency should be justified by symptom severity; PRN dosing preferred once stable.

3. Tab. Metolazone 5mg TDS - IRRATIONAL / HIGH CONCERN

• Efficacy: Metolazone acts on the distal convoluted tubule and synergizes with loop diuretics (furosemide/torsemide) in refractory edema. However, its use is indicated only when loop diuretics alone are insufficient.
• Safety: The major concern here is that this patient is already on THREE diuretics simultaneously - furosemide 100mg TDS, torsemide 100mg TDS, and spironolactone 100mg TDS. Adding metolazone on top creates extreme risk of:
  • Severe hypovolemia and circulatory collapse (nephrotic patients may already have reduced effective circulating volume)
  • Dangerous hypokalemia (loop + thiazide without adequate potassium replacement)
  • Acute kidney injury from over-diuresis
  • Brenner & Rector's The Kidney notes: "The combination of a thiazide diuretic with furosemide dissipates edema but at the expense of marked kaliuresis"
• Dose: 5mg TDS is very aggressive for an adolescent. Typical use is 2.5-5mg ONCE daily, with careful monitoring.
• Cost: Low cost, but the risk-benefit ratio is unfavorable given the concurrent diuretic burden.
• Verdict: ❌ Irrational - quadruple diuretic regimen (furosemide + torsemide + spironolactone + metolazone) is dangerous. Metolazone may be justifiable only in truly refractory edema as a short-term add-on to one loop diuretic, not both. This combination requires urgent review.

4. Tab. Aldactone (Spironolactone) 100mg TDS - IRRATIONAL DOSE / COMBINATION CONCERN

• Efficacy: Spironolactone is rational in nephrotic syndrome as it counteracts secondary hyperaldosteronism and helps preserve potassium lost via loop diuretics.
• Safety: 100mg TDS = 300mg/day, which is an extremely high dose for a 16-year-old. Standard pediatric/adolescent dosing is 1-3mg/kg/day in divided doses. For a 50-60kg adolescent, this would be 50-180mg/day. 300mg/day exceeds safe limits and risks severe hyperkalemia (especially dangerous if renal function is impaired in nephrotic syndrome). Combined with concurrent loop diuretics and metolazone, the net electrolyte effect is unpredictable and dangerous.
• Cost: Spironolactone is inexpensive and widely available in India.
• Verdict: ❌ Irrational dose - 300mg/day is excessive for this age/weight. Dose reduction to 1-2mg/kg/day (50-100mg/day max) with electrolyte monitoring is required.

5. Inj. Furosemide (Lasix) 100mg TDS - IRRATIONAL DOSE / COMBINATION

• Efficacy: Furosemide is the first-line diuretic in nephrotic syndrome. Per Tintinalli's Emergency Medicine: furosemide at 1-2mg/kg is recommended, with albumin infusion first if there is profound hypoalbuminemia.
• Safety: For a 16-year-old (~50-60kg), 100mg TDS = 300mg/day is a very high dose. Standard pediatric dosing is 1-2mg/kg/dose, which would be 50-120mg/day total. Additionally, using BOTH furosemide AND torsemide (two loop diuretics) simultaneously is pharmacologically redundant and dangerous - they compete for the same tubular receptor (NKCC2 on the thick ascending limb of loop of Henle). Dual loop diuretic use is not supported by any guideline and creates cumulative toxicity risk (ototoxicity, nephrotoxicity, severe electrolyte disturbance).
• Cost: Furosemide is among the cheapest diuretics available.
• Verdict: ❌ Irrational - dose is excessive AND concurrent use with torsemide (another loop diuretic) is pharmacologically unsound. One loop diuretic should be chosen.

6. Inj. Dytor (Torsemide) 100mg TDS - IRRATIONAL (DUPLICATE LOOP DIURETIC)

• Efficacy: Torsemide has better oral bioavailability and longer duration than furosemide. Goodman & Gilman notes torsemide may be superior to furosemide in heart failure but for nephrotic syndrome both are equivalent. There is NO clinical rationale to use both simultaneously.
• Safety: Using torsemide 100mg TDS alongside furosemide 100mg TDS means 600mg/day total loop diuretic equivalent - this is extreme and risks:
  • Severe dehydration and hemodynamic compromise
  • Acute tubular necrosis
  • Sensorineural hearing loss (loop diuretic ototoxicity is dose-dependent)
  • Severe hyponatremia and hypokalemia
• Cost: Torsemide (brand: Dytor) is significantly more expensive than furosemide in India.
• Verdict: ❌ Strongly irrational - simultaneous use of two loop diuretics is contraindicated. Either furosemide OR torsemide should be used, not both.

7. Tab. Dolo (Paracetamol) 650mg TDS - CONDITIONALLY RATIONAL

• Efficacy: Paracetamol is an appropriate first-line analgesic/antipyretic in nephrotic syndrome. NSAIDs (ibuprofen, diclofenac) are contraindicated in nephrotic syndrome due to prostaglandin-mediated reduction in GFR, worsening renal function and edema.
• Safety: Safe at 650mg TDS in a 16-year-old (generally >40kg). The choice of paracetamol over NSAIDs is correct. However, TDS should only be continued as long as there is active fever or pain - not as a standing order without indication.
• Cost: Paracetamol (Dolo brand) is inexpensive.
• Verdict: ✅ Rational drug choice (avoids NSAIDs appropriately), but duration should be need-based.

8. Inj. Human Albumin 20% 100mL - RATIONAL

• Efficacy: Per Tintinalli's Emergency Medicine: "infusion of albumin (0.5 to 1.0g/kg) followed by furosemide may be effective" when diuretics fail due to profound hypoalbuminemia. The 2024 Ashford St. Peter's guideline recommends discussing with pediatric nephrology if 20% albumin is required. 100mL of 20% albumin = 20g albumin.
• Safety: Should be followed by a loop diuretic to prevent fluid redistribution back into interstitium. Rapid infusion risk of fluid overload. Intensive monitoring required.
• Cost: Human albumin is expensive. It is reserved for severe hypoalbuminemia (<15-20g/L) unresponsive to diuretics alone. If albumin is low, this is clinically justified despite cost.
• Verdict: ✅ Rational if albumin is <20g/L and edema is refractory to diuretics. Cost is high but clinically justified in the right setting.

9. Inj. Methylprednisolone 500mg in 100mL NS - RATIONAL (PULSE THERAPY)

• Efficacy: Methylprednisolone IV pulse at 500-1000mg is used in steroid-resistant nephrotic syndrome or severe relapses. The KDIGO 2025 Guideline states that "oral prednisolone in combination with 3 daily i.v. methylprednisolone pulses can be considered" in partial responders. Literature (Brenner & Rector's) supports pulse methylprednisolone for severe idiopathic childhood nephrotic syndrome.
• Safety: 500mg pulse is standard. Risks include hypertension, hyperglycemia, infection, fluid retention. Requires blood glucose monitoring. The concurrent pantoprazole prescription is appropriate gastroprotection.
• Cost: IV methylprednisolone is moderately expensive but justified for the indication.
• Verdict: ✅ Rational - appropriate indication for pulse therapy in a hospital setting with gastroprotection co-prescribed.

10. Tab. Omaroxtil 30mg OD - UNCERTAIN / NEEDS CLARIFICATION

• Verdict: ⚠️ Cannot fully assess without confirming the drug identity. If it is an antibiotic (e.g., amoxicillin), it is rational as prophylaxis.

Summary Table

Critical Safety Concerns Requiring Urgent Review

1. Simultaneous furosemide + torsemide (both loop diuretics): Pharmacologically irrational - same receptor, additive toxicity. One must be discontinued immediately.
2. Triple/quadruple diuretic regimen: Furosemide + Torsemide + Spironolactone + Metolazone together is extremely aggressive and poses serious risk of acute kidney injury, electrolyte crisis, and hemodynamic collapse in a 16-year-old. Diuretic rationalization is urgent.
3. Spironolactone overdose: 300mg/day for this patient's age and weight exceeds recommended dosing.
4. Electrolyte monitoring: If this regimen is maintained, serum K+, Na+, creatinine, and urine output must be monitored every 4-6 hours.

Cost Assessment

• KDIGO 2025 Clinical Practice Guideline for Nephrotic Syndrome in Children
• Tintinalli's Emergency Medicine - Treatment of Nephrotic Syndrome, p.924
• Brenner & Rector's The Kidney - Nephrotic Syndrome management, diuretic therapy
• Ashford St. Peter's Paediatric Nephrotic Syndrome Guideline, May 2024
• Goodman & Gilman's The Pharmacological Basis of Therapeutics - Diuretics
• PMID: 34091756 - Pediatric steroid-sensitive nephrotic syndrome: German best practice guideline (S2e)

Updated Rationality Assessment - Based on Medication Chart

Key Clarification from Chart

Drug-by-Drug Assessment with Administration Pattern Analysis

1. Inj. Pantoprazole (Pan) 40mg OD - ✅ RATIONAL

• Indication on chart: Gastro-protection
• Administration: Given every single day (Day 15 to Day 2) - consistent.
• Efficacy: Correct co-prescription with corticosteroids (methylprednisolone pulse + oral prednisolone). PPIs are standard gastroprotection with high-dose steroids in nephrotic syndrome per KDIGO 2025 and Ashford-St.Peter's 2024 guideline.
• Safety: Safe for this age. OD IV is appropriate while inpatient.
• Cost: Low-cost, widely available generic. Rational choice.
• Pattern note: On days when methylprednisolone was NOT given (most days), oral prednisolone (Omacortil) justifies continued PPI. Continuing throughout the admission is appropriate.
• Verdict: ✅ Rational - correct indication, dose, frequency, and duration.

2. Inj. Emeset (Ondansetron) 4mg TDS - ⚠️ CONDITIONALLY RATIONAL

• Indication on chart: Nausea and vomiting
• Administration: Given every single day for 14 days continuously at TDS (3 times/day).
• Efficacy: Ondansetron is appropriate for steroid-related nausea. However, administering it TDS for 14 consecutive days as a standing order is excessive.
• Safety: Prolonged TDS use carries cumulative risk of QTc prolongation, particularly relevant in a patient who may have electrolyte disturbances (hypokalemia from diuretics). Hypokalemia + QTc prolongation from ondansetron = cardiac risk.
• Cost: Generic ondansetron is affordable, but 14 days TDS IV = 42 injections - unnecessarily high cost for a drug that should be PRN.
• Pattern concern: Should have been converted to PRN or stepped down to oral/once-daily after the first 2-3 days if vomiting was not persistent.
• Verdict: ⚠️ Irrational duration and frequency - drug is appropriate but should be PRN, not standing TDS for 14 days.

3. Tab. Metolazone 5mg TDS - ❌ IRRATIONAL

• Indication on chart: Management of edema
• Administration: Given every day for 14 days continuously at TDS.
• Safety: Critical concern. This patient received metolazone 5mg TDS (15mg/day) EVERY DAY for 14 days alongside furosemide TDS and torsemide TDS and spironolactone TDS. This quadruple diuretic regimen over 2 weeks poses serious, ongoing risk of:
  • Cumulative electrolyte wasting (K+, Na+, Mg²+)
  • Progressive hypovolemia despite peripheral edema (due to low oncotic pressure in nephrotic syndrome)
  • Acute kidney injury from over-diuresis
• Dose issue: 5mg TDS = 15mg/day. Standard use is 2.5-5mg OD only, briefly, as an add-on when loop diuretics fail.
• Duration issue: 14 consecutive days of metolazone is far beyond standard use (usually 1-3 days maximum as a short burst).
• Cost: Metolazone is cheap, but the clinical risk greatly outweighs any cost benefit.
• Verdict: ❌ Strongly irrational - excessive dose (15mg/day), prolonged duration (14 days), and dangerous combination with two other loop diuretics + spironolactone.

4. Tab. Aldactone (Spironolactone) 100mg TDS - ❌ IRRATIONAL DOSE

• Indication on chart: Edema / fluid overload
• Administration: Given almost every day (missed only on Day 2).
• Efficacy: Spironolactone is rational in nephrotic syndrome for its aldosterone-blocking and potassium-sparing effects.
• Dose concern: 100mg TDS = 300mg/day. For a 16-year-old (~50-60kg), the recommended dose is 1-3mg/kg/day. Even at the upper end, maximum would be ~180mg/day. 300mg/day is 67-100% above the recommended maximum.
• Electrolyte paradox: Spironolactone retains potassium while metolazone + furosemide + torsemide waste potassium. The electrolyte balance in this patient must be highly unstable - erratic and unpredictable K+ levels over 14 days.
• Cost: Spironolactone is inexpensive, but the supra-therapeutic dose delivers no additional benefit and increases risk.
• Verdict: ❌ Irrational dose - should be reduced to 50-100mg/day with daily electrolyte checks.

5. Inj. Furosemide (Lasix) 100mg TDS - ❌ IRRATIONAL (DUPLICATE + DOSE)

• Indication on chart: Edema / active fluid overload
• Administration: Given daily Days 15-26 and 1-2, with one omission on Day 18. Notably, torsemide was NOT given on Days 15-16 when furosemide was given - suggesting a possible intended transition, but then both were run simultaneously from Day 17 onward.
• Critical finding from chart: From Day 17 to Day 26 (at minimum), BOTH furosemide 100mg TDS AND torsemide 100mg TDS were given simultaneously = 200mg TDS loop diuretic equivalent = 600mg/day of combined loop diuretics.
• Pharmacology: Both target the same Na-K-2Cl cotransporter (NKCC2) in the loop of Henle. Concurrent use is pharmacologically irrational - there is no additional tubular receptor to act on. The combined effect is unpredictable toxicity, not enhanced efficacy.
• Safety: 600mg/day equivalent loop diuretic for ~10 days = high cumulative risk of ototoxicity, nephrotoxicity, severe hypokalemia.
• Cost: Furosemide is the cheapest loop diuretic - adding torsemide doubles the cost without benefit.
• Verdict: ❌ Strongly irrational - dual loop diuretic from Day 17 onward. One should have been stopped when the other was started.

6. Inj. Dytor (Torsemide) 100mg TDS - ❌ IRRATIONAL (DUPLICATE)

• Indication on chart: Edema
• Administration: NOT given Days 15-16, but given from Day 17 to Day 2 (approximately 12 days). This confirms that it was introduced WHILE furosemide was already running, creating dual loop diuretic therapy.
• Torsemide vs Furosemide: Torsemide has superior oral bioavailability (80% vs 50% for furosemide) and longer duration of action. If edema was not responding to furosemide, the rational approach would have been to SWITCH to torsemide, not add it on top.
• Dose: 100mg TDS is very high even as monotherapy.
• Cost: Torsemide (brand Dytor) is significantly more expensive than furosemide. Using both is costly and redundant.
• Verdict: ❌ Irrational - should replace furosemide, not be added to it. Introduction on Day 17 while furosemide continued is a prescribing error.

7. Tab. Dolo (Paracetamol) 650mg TDS - ✅ RATIONAL (LIMITED USE)

• Indication on chart: Relief of fever
• Administration: Given ONLY on Day 18 and Day 19 (2 days only), then stopped.
• This is the most rational prescribing pattern in the entire chart. Paracetamol was used for 2 days for fever and appropriately discontinued.
• Drug choice: Correct - avoids NSAIDs which are contraindicated in nephrotic syndrome (reduce GFR via prostaglandin inhibition, worsen proteinuria and edema).
• Cost: Minimal (2 days only).
• Verdict: ✅ Rational - correct drug, appropriate dose for age, used only when indicated, promptly stopped.

8. Inj. Human Albumin 20% 100mL - ✅ RATIONAL (APPROPRIATE TIMING)

• Indication on chart: Hypoalbuminemia
• Administration: Given on Day 18 ONLY - a single infusion.
• Chart significance: Day 18 is also the day furosemide was NOT given and paracetamol was started (fever). The albumin infusion on Day 18 was likely timed for a clinical deterioration episode - refractory edema with profound hypoalbuminemia during a febrile episode.
• Efficacy: Per Tintinalli's Emergency Medicine, albumin 0.5-1g/kg followed by furosemide is appropriate when diuretics fail in severe hypoalbuminemia. The single targeted use here is appropriate.
• Safety: Single dose with clinical justification is appropriate. Intensive monitoring required (the chart shows furosemide was withheld same day, possibly to avoid overload).
• Cost: Expensive (~INR 3,000-6,000 per 100mL vial in India), but single-use targeting is cost-justified given clinical indication.
• Verdict: ✅ Rational - single targeted infusion for a specific clinical event is evidence-based and cost-justified.

9. Methylprednisolone 500mg IV - ✅ RATIONAL (PULSE THERAPY, APPROPRIATE TIMING)

• Indication on chart: Immunosuppression / anti-inflammatory
• Administration: Given on Day 25 ONLY - a single pulse.
• Clinical context: This represents a single IV pulse of methylprednisolone, likely given when the oral prednisolone (Omacortil, started Day 1-2 of next month) was being introduced or when there was partial response to oral steroids. KDIGO 2025 recommends 3 daily IV methylprednisolone pulses for partial responders as an option.
• Concern: Only 1 pulse is documented. Standard pulse protocols call for 3 consecutive daily pulses (500-1000mg). A single pulse may represent an incomplete course or an isolated acute intervention. The rationale for a single pulse vs. a full 3-pulse course needs clinical justification.
• Safety: Concurrent pantoprazole, blood glucose monitoring (should be confirmed), BP monitoring required.
• Cost: IV methylprednisolone 500mg is moderately expensive but justified for the indication.
• Verdict: ✅ Rational drug/dose - but only 1 of a typical 3-pulse course documented; may be incomplete.

10. Tab. Omacortil (Prednisolone) 30mg OD - ✅ RATIONAL

• Indication on chart: (Same as methylprednisolone - immunosuppression)
• Administration: Given on Day 1 and Day 2 (i.e., at the end of the documented inpatient period - these are the "next month" dates on the chart).
• Clinical context: Oral prednisolone 30mg OD is started at the end of admission/discharge - this represents the transition from IV pulse methylprednisolone to maintenance oral corticosteroid therapy, which is standard practice.
• Dose: 30mg OD for a 16-year-old is within standard range (typically 1mg/kg/day up to 60mg/day). KDIGO 2025 and standard protocols recommend prednisolone 2mg/kg/day (max 60mg) for initial therapy. At 30mg, this may be a post-pulse maintenance dose or a weight-appropriate dose for a lighter adolescent (~30kg would give 1mg/kg).
• Safety: Appropriate transition from IV to oral. Pantoprazole is co-prescribed throughout, which is correct.
• Cost: Prednisolone (Omacortil) is among the cheapest oral steroids available in India (INR 2-5 per tablet).
• Verdict: ✅ Rational - appropriate oral corticosteroid transition at end of inpatient care.

Timeline Analysis - What the Chart Reveals

Days 15-16:   Furosemide alone (no torsemide yet) - Rational start
Day 17:       Torsemide ADDED alongside furosemide - First irrational point
Day 18:       Furosemide withheld; Albumin given; Paracetamol started - Clinical deterioration/fever episode
Days 19-26:   BOTH furosemide + torsemide resumed - Dual loop diuretic period (10 days)
Day 25:       Single IV methylprednisolone pulse - Steroid escalation
Days 1-2:     Oral prednisolone started; spironolactone stopped on Day 2 - Transition to oral therapy

Overall Summary Table

Top Prescribing Issues Identified from Chart

1. Dual loop diuretic (Days 17-26+): Furosemide and torsemide both given TDS simultaneously for ~10 days. No pharmacological justification. Either drug alone would suffice; together they create compounded toxicity with no additional benefit.
2. Metolazone 5mg TDS for 14 consecutive days: This drug is meant for short bursts (1-3 days). Continuous 14-day use at 3x the standard dose, alongside two loop diuretics, is a major prescribing concern.
3. Spironolactone 300mg/day: Significantly above the recommended ceiling for this age. No dose reduction documented over 13 days despite likely improving edema.
4. Ondansetron TDS for 14 days standing: Should have been PRN or stepped down after 2-3 days; 14-day TDS standing order is not evidence-based.
5. Single methylprednisolone pulse only: Standard protocol calls for 3 consecutive daily pulses. Only 1 pulse documented - course appears incomplete or rationale for single-pulse needs documentation.

• Furosemide (Lasix): Days 15, 16, 17 only (3 days) - then stopped
• Torsemide (Dytor): Started Day 17 (overlap for 1 day), then continued as the primary loop diuretic from Day 18 onward

Revised Diuretic Rationality Assessment

5. Inj. Furosemide 100mg TDS - ✅ REVISED: RATIONAL (Short-term initial therapy)

• Duration: 3 days (Days 15-17) - appropriate short-term loop diuresis for acute edema management at admission
• Transition: Switched to torsemide from Day 17 onward - this is a rational decision. Torsemide has better and more predictable oral/IV bioavailability (~80%) compared to furosemide (~50%), making it preferable for sustained diuresis in nephrotic syndrome
• Dose concern remains: 100mg TDS is still on the higher end for a 16-year-old (~1.5-2mg/kg assuming 50-60kg body weight, which is borderline acceptable)
• Verdict: ✅ Rational - short initial use, appropriately transitioned to torsemide

6. Inj. Torsemide 100mg TDS - ⚠️ CONDITIONALLY RATIONAL (Revised)

• Duration: ~12 days (Day 17 to Day 2) as the primary loop diuretic after furosemide was stopped
• Rationale for switch: Appropriate - torsemide's more predictable absorption and longer half-life makes it better suited for sustained diuresis in nephrotic syndrome where gut wall edema reduces furosemide absorption
• Dose concern remains: 100mg TDS = 300mg/day is still high for this age. Standard guidance suggests 10-40mg/day for edema; 300mg/day is well above this range
• Duration concern: 12 days of high-dose torsemide without documented dose reduction as edema improves is questionable
• Verdict: ⚠️ Rational drug choice and rational switch FROM furosemide, but dose (300mg/day) is excessive and should have been titrated down as clinical response occurred

Revised Overall Diuretic Strategy Summary

Revised Priority Concerns (Updated)

1. Torsemide 300mg/day - dose needs titration downward as edema responds; no evidence of dose reduction over 12 days
2. Metolazone 15mg/day for 14 days - still the most irrational element; excessive dose and far too prolonged
3. Spironolactone 300mg/day - still above recommended ceiling for this age/weight
4. Ondansetron TDS for 14 days standing - should have been PRN

Brief Note on Overall Prescription Rationality

Nephrotic Syndrome | 16-year-old | 14-day Inpatient Course

What Was Done Well ✅

• Corticosteroid strategy is appropriate: IV methylprednisolone pulse followed by transition to oral prednisolone (Omacortil) is consistent with KDIGO 2025 guidelines for nephrotic syndrome in children aged 1-18 years.
• Furosemide-to-torsemide transition is rational: Starting with furosemide for 3 days and switching to torsemide (better bioavailability, more predictable diuresis in nephrotic patients with gut wall edema) reflects sound clinical thinking.
• Albumin used appropriately: Single targeted infusion on Day 18 during an acute deterioration - not overused, not underused.
• Paracetamol used correctly: Given only 2 days for fever, then stopped. NSAIDs were correctly avoided (nephrotoxic in nephrotic syndrome).
• Gastroprotection maintained throughout: Pantoprazole co-prescribed for the full duration of steroid therapy - correct and guideline-consistent.

What Needs Improvement ⚠️

• Torsemide dose not titrated: 100mg TDS (300mg/day) maintained for 12 days without documented step-down as edema responded. Clinical practice requires diuretic de-escalation once therapeutic goals are met.
• Spironolactone overdosed: 300mg/day far exceeds the recommended 1-3mg/kg/day for this age. Should not exceed 100-150mg/day for a typical 50-60kg adolescent.
• Metolazone overused: 5mg TDS for 14 consecutive days is the most irrational element of this prescription. Metolazone is intended as a short-term (1-3 day) burst add-on for refractory edema, not a standing 14-day TDS prescription. The dose of 15mg/day also exceeds standard recommendations.
• Ondansetron given as a standing TDS for 14 days: Should have been prescribed PRN after the first 2-3 days. Prolonged standing TDS without documented ongoing vomiting is irrational and risks QTc prolongation in a patient already at risk of electrolyte disturbance.
• Methylprednisolone pulse appears incomplete: Only 1 pulse documented; standard protocol is 3 consecutive daily pulses.

Rational Score

Drug Profile Notes: 16-Year-Old Female with Nephrotic Syndrome (Facial + Lower Limb Edema)

1. Inj. Pantoprazole 40mg OD

2. Inj. Ondansetron (Emeset) 4mg TDS

3. Tab. Metolazone 5mg TDS

• Already hypoalbuminemic - diuresis reduces effective circulating volume, not just edema
• Risk of prerenal azotemia and acute kidney injury with prolonged use
• Hypokalemia risk compounded by concurrent torsemide
• Hypomagnesemia can independently trigger cardiac arrhythmias
• No pediatric-specific dosing data; dosing extrapolated from adults

4. Tab. Spironolactone (Aldactone) 100mg TDS

• Hyperkalemia - life-threatening, especially if renal function deteriorates
• Anti-androgenic effects - spironolactone blocks androgen receptors; in a female adolescent this causes menstrual irregularities and may affect hormonal development at high chronic doses
• Gynecomastia equivalent - in females, breast tenderness and hormonal disruption
• At 300mg/day, therapeutic benefit plateaus while toxicity risk rises steeply

5. Inj. Furosemide (Lasix) 100mg TDS (Days 1-3)

6. Inj. Torsemide (Dytor) 100mg TDS

• Better oral/IV bioavailability (80-90% vs 50% for furosemide), less affected by gut wall edema
• Longer duration of action (6-8 hours vs 4-6 hours), providing more consistent diuresis
• Less bound to albumin relatively, so more drug reaches the tubular lumen in hypoalbuminemic states The switch from furosemide to torsemide is clinically well-reasoned.

7. Tab. Paracetamol (Dolo) 650mg TDS

• NSAIDs inhibit prostaglandin-mediated afferent arteriolar dilation, reducing GFR
• Worsen sodium and water retention, aggravating edema
• Increase proteinuria Paracetamol has none of these effects. Short 2-day course eliminates hepatotoxicity risk.

8. Inj. Human Albumin 20% 100mL

• Fluid overload if given without concurrent diuretic
• Pulmonary edema (particularly relevant since the chart shows furosemide was withheld on the same day - this needs clarification; standard practice is to give albumin followed by a loop diuretic)
• Infection transmission risk (minimized with modern pasteurized products)
• Allergic reactions (rare) In a 16-year-old female, no specific hormonal or developmental concerns.

9. Inj. Methylprednisolone 500mg IV Pulse

• Hypertension - acute BP elevation during infusion; monitoring mandatory
• Hyperglycemia - transient but significant; blood glucose monitoring required
• Menstrual irregularities - high-dose steroids suppress the hypothalamic-pituitary-ovarian axis; relevant in an adolescent female
• Bone health - even single pulses contribute to cumulative steroid exposure; calcium and vitamin D supplementation should be considered in an adolescent female where bone mineral density accrual is still occurring
• Mood/behavioral effects - steroid psychosis and mood swings are more pronounced with IV pulse therapy Only 1 pulse documented; if this was meant to be a 3-pulse course, the incomplete course reduces efficacy without reducing toxicity risk proportionally.

10. Tab. Omacortil (Prednisolone) 30mg OD

• Growth: Prolonged steroid use suppresses growth hormone axis - less critical at 16 (near completion of growth) but still relevant
• Bone density: Adolescent females are at peak bone mineral accrual age; corticosteroids reduce calcium absorption and increase bone resorption. Calcium + Vitamin D supplementation is strongly recommended (notably absent from this prescription)
• Menstrual cycle disruption: Common with systemic steroids in adolescent females
• Cushingoid features: Weight gain, facial puffiness, striae - psychologically significant for a teenage girl
• Adrenal suppression: With prolonged use; must not be stopped abruptly
• Infection risk: Increased susceptibility to varicella, pneumococcal infections - vaccination status should be reviewed

Patient-Specific Summary

What the chart contains:

• 🟢 Green = Rational (Pantoprazole, Furosemide short-term, Paracetamol, Albumin)
• 🟡 Yellow = Conditional concern (Ondansetron, Torsemide, Methylprednisolone, Prednisolone)
• 🔶 Orange = Dose adjustment flagged (Spironolactone, Torsemide)
• 🔴 Red = Irrational - high risk (Metolazone)
• 🟣 Purple = Recommended addition (Calcium + Vitamin D - absent from original prescription)